bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related.

Geelen, F. A. M. J.; Vermeer, Maarten H.; Meijer, Chris J.L.M.; Putte, S. C. J. van der; Kerkhof, Esther van de; Kluin, Philippus; Willemze, Rein

doi:10.1200/jco.1998.16.6.2080

Cited by 133 publications

(108 citation statements)

References 18 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, this FOXP1 expressing subset of DLBCL showed additional genotypic and phenotypic similarities to primary cutaneous large B-cell lymphoma, leg type including expression of Mum1/IRF4, expression of Bcl-2 in absence of chromosomal translocation t(14;18) and an ABC gene expression profile. 8,26,27 In another study, the chromosomal translocation t(3;14) involving FOXP1 and IGH genes could be demonstrated in only one out of 10 FOXP1 expressing DLBCL cases as a underlying mechanism of FOXP1 protein expression. 28 Using a fluorescent in situ hybridization (FISH)-analysis, we did not detect the chromosomal translocation t(3;14) in any of the 11 PCLBCL, leg-type cases of the present study (data not shown).…”

Section: Discussionmentioning

confidence: 94%

Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma

et al. 2006

View full text Add to dashboard Cite

Expression patterns of eight transcription factors involved in different stages of B-cell development were investigated in a large group of primary cutaneous B-cell lymphomas and compared with expression patterns during normal B-cell development. The following transcription factors were investigated: Pax-5, PU.1, Oct2, BOB.1, Bcl-6, Mum1/IRF4, Blimp-1 and FOXP1. Primary cutaneous large B-cell lymphomas, leg type showed aberrant coexpression of Bcl-6 and Mum1/IRF4 and in addition strong expression of FOXP1. Expression of FOXP1 and Mum1/IRF4 strongly suggests an activated B-cell type of origin. In contrast, primary cutaneous follicle center lymphomas showed expression of Bcl-6, Pax-5, PU.1, Oct2 and BOB.1, but not of Mum1/IRF4, Blimp-1 and FOXP1. Primary cutaneous marginal zone B-cell lymphoma showed expression of Pax-5, PU.1, Oct2 and BOB.1, but not Bcl-6 by the neoplastic B-cells, and Mum1/IRF4 and Blimp-1 by the neoplastic plasma cells. In conclusion, in primary cutaneous follicle center lymphoma and primary cutaneous marginal zone B-cell lymphoma expression patterns were observed similar to their supposed benign counterparts, germinal center B-cells and postgerminal center B-cells, respectively, which might reflect their indolent clinical behaviour and excellent prognosis. In contrast, the activated B-cell expression pattern in the group of primary cutaneous large B-cell lymphoma, leg type may contribute to its poor prognosis and Mum1/IRF4 and FOXP1 may serve as additional diagnostic markers for this type of primary cutaneous B-cell lymphoma.

show abstract

Section: Discussionmentioning

confidence: 94%

Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma

et al. 2006

View full text Add to dashboard Cite

show abstract

“…43 However, it has been demonstrated that the increased bcl-2 expression in a series of PCLBCLs was not associated with the t(14;18). 26 Pathologic mechanisms other than the t(14;18) may increase the expression of bcl-2, as has been hypothesized in noncutaneous lymphomas. 29,30 Beside bcl-2 protein expression, other prognostic factors in PCLBCL must be taken into account.…”

Section: Discussionmentioning

confidence: 99%

“…8,26 Therefore, it could be suspected that factors other than location might dictate the prognosis of PCLBCL.…”

mentioning

confidence: 99%

Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas

Grange

Petrella

Beylot‐Barry

et al. 2004

Blood

126

View full text Add to dashboard Cite

Bcl-2 protein expression has been associated with poor prognosis in patients with noncutaneous diffuse large B-cell lymphomas. In primary cutaneous large B-cell lymphomas, the location on the leg, the round-cell morphology defined as the predominance of centroblasts and immunoblasts over large centrocytes, and multiple skin lesions were identified as adverse prognostic factors. The prognostic value of bcl-2 protein expression has not been studied in large series of patients. We evaluated 80 primary cutaneous large B-cell lymphomas collected by the French Study Group on Cutaneous Lymphomas. The prognostic value of age, sex, number of lesions, cutaneous extent, location, serum lactate dehydrogenase (LDH) level, B symptoms, morphology, and bcl-2 protein expression was studied. The overall 5-year specific survival rate was 65%. In univariate analysis, advanced age, multiple skin lesions (n ‫؍‬ 48), location on the leg (n ‫؍‬ 25), round-cell morphology (n ‫؍‬ 32), and bcl-2 expression (n ‫؍‬ 39) were significantly related to death from lymphoma. In multivariate analysis, bcl-2 expression (P ‫؍‬ .0003), multiple skin lesions (P ‫؍‬ .004), and age remained independent prognostic factors. The 5-year specific survival rates in bcl-2-positive and bcl-2-negative patients were 41% and 89%, respectively (P < .0001). A new prognostic classification of primary cutaneous B-cell lymphoma should be based primarily on bcl-2 protein expression rather than the location of skin lesions. (Blood. 2004;103: 3662-3668)

show abstract

“…A prominent stromal reaction as seen in PCFCLs is not observed. In contrast to the group of PCFCLs, PCLBCL, leg type, shows strong bcl-2 expression, also in cases not located on the legs [14]. Bcl-6 is expressed by most cases, whereas CD10 staining is generally absent [15].…”

Section: Discussionmentioning

confidence: 93%